NCI-H1648 - Cell Line (ID:50032)
| HMS LINCS ID: | 50032 |
| Name: | NCI-H1648 |
| Alternative Names: | H1648 |
| LINCS ID: | LCL-1632 |
| Alternative ID: | CLO_0008006 |
| Parent Cell Line: | |
| Reference Source: | ATCC CRL-5882 |
| Organism: | Homo sapiens |
| Organ: | lung |
| Tissue: | |
| Cell Type: | |
| Details of Cell Type: | |
| Donor Sex: | male |
| Donor Age: | |
| Donor Ethnicity: | |
| Donor Health Status: | |
| Disease: | DOID:3910, lung adenocarcinoma |
| Details of Disease: | NSCLC adenocarcinoma |
| Production Details: | |
| Genetic Modification(s): | none |
| Known Mutations: | |
| Citation Information for Mutations: | COSS687799 |
| Verification Reference Profile: | DNA Profile (STR, source: ATCC): Amelogenin: X,Y CSF1PO: 10,12 D13S317: 12 D16S539: 11 D5S818: 11 D7S820: 10,11 THO1: 7,9.3 TPOX: 8,11 vWA: 14,17 |
| Growth Properties: | adherent |
| Recommended Culture Conditions: | From MGH/CMT as specified by cell provider: ACL-4 medium (serum-free). ACL-4 medium is formulated at the ATCC as follows: A 1:1 mixture of Ham's F12 medium with 2.5 mM L-glutamine and Dulbecco's Modified Eagle's Medium adjusted to contain 1.2 g/L sodium bicarbonate (available as ATCC 30-2006) with additional supplements at the concentrations below: 0.02 mg/ml insulin 0.01 mg/ml transferrin 25 nM sodium selenite 50 nM Hydrocortisone 1 ng/ml Epidermal Growth Factor (do not filter) 0.01 mM ethanolamine 0.01 mM phosphorylethanolamine 100 pM triiodothyronine 0.5% (w/v) bovine serum albumin 10 mM HEPES 0.5 mM sodium pyruvate 2mM L-glutamine |
| Relevant Citations: | |
| Usage Note: | |
| Comments: | |
| Date Publicly Available: | 2012-04-25 |
| Most Recent Update: | 2016-04-04 |
Batch Information for HMSL50032-1:
| HMS LINCS Batch ID: | 50032-1 |
| Provider: | Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) |
| Provider Catalog ID: | MGH-1245 |
| Provider Batch ID: | |
| Source Information: | Obtained by Nathan Moerke (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes). |
| Date Received: | |
| HMS QC Outcome: | |
| Transient Modification(s): | |
| Comments: | |
| Date Publicly Available: | 2012-04-25 |
| Most Recent Update: | 2015-06-29 |